FDA begins move to unveil secret data

For years the FDA has kept a mother lode of data on drugs and devices under wraps, careful to protect developers' trade secrets. But new leadership at the FDA wants to open some of that data to public scrutiny to help satisfy critics unhappy about the agency's uneven record on drug safety. A more open approach to data would save lives, they say. But biopharma companies will be watching closely to make sure they aren't damaged in the move toward greater transparency. Report [1]